Last reviewed · How we verify
LEO 80190
LEO 80190 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin.
LEO 80190 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin. Used for Atopic dermatitis, Psoriasis.
At a glance
| Generic name | LEO 80190 |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting phosphodiesterase 4, LEO 80190 increases intracellular cAMP levels in immune and inflammatory cells, suppressing the release of pro-inflammatory mediators such as TNF-α and IL-23. This mechanism reduces skin inflammation and is designed for topical treatment of inflammatory skin conditions.
Approved indications
- Atopic dermatitis
- Psoriasis
Common side effects
- Application site irritation
- Application site pain
- Headache
Key clinical trials
- Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds (PHASE3)
- A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas (PHASE3)
- Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |